Drug Profile

Ephedrine injection - Sintetica

Alternative Names: Ephedrine hydrochloride injection - Sintetica; ET-203; Rezipres

Latest Information Update: 29 Jun 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sintetica
Developer Eton Pharmaceuticals
Class Analgesics; Antihypotensives; Decongestants; Propanolamines; Small molecules
Mechanism of Action Alpha adrenergic receptor agonists; Beta adrenergic receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Hypotension

Most Recent Events

24 Jun 2022 Dr Reddy's Laboratories acquires ephedrine form Eton Pharmaceuticals
13 Apr 2022 Eton Pharmaceuticals plans to launch the vial presentation of ephedrine hydrochloride injection in 2022 (Form 10K, December 2021, Eton Pharmaceuticals)
14 Mar 2022 Launched for Hypotension in USA (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com